• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 3. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548

Introduction to 2,7-Dimethylimidazo[1,2-a]pyridin-3-amine (CAS No. 8012-91-7)

2,7-Dimethylimidazo[1,2-a]pyridin-3-amine, identified by its Chemical Abstracts Service (CAS) number 8012-91-7, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the imidazopyridine class, a structural motif known for its diverse biological activities and potential therapeutic applications. The presence of nitrogen atoms in both the imidazole and pyridine rings contributes to its unique electronic properties and reactivity, making it a valuable scaffold for the development of novel bioactive molecules.

The structure of 2,7-Dimethylimidazo[1,2-a]pyridin-3-amine features a fused ring system consisting of an imidazole ring connected to a pyridine ring at the 1 and 2 positions, respectively. The substitution of methyl groups at the 2 and 7 positions enhances its stability and influences its interactions with biological targets. The amine functional group at the 3-position provides a site for further chemical modification, enabling the synthesis of derivatives with tailored pharmacological properties.

One of the most compelling aspects of 2,7-Dimethylimidazo[1,2-a]pyridin-3-amine is its potential as a pharmacophore in drug discovery. Over recent years, there has been a surge in research focused on identifying new molecular entities with therapeutic efficacy. The imidazopyridine scaffold has been extensively studied for its role in modulating various biological pathways, including those involved in inflammation, cancer, and infectious diseases. Preclinical studies have demonstrated that derivatives of this compound exhibit promising activities as kinase inhibitors, antimicrobial agents, and anti-inflammatory compounds.

In particular, the biological activity of 2,7-Dimethylimidazo[1,2-a]pyridin-3-amine has been explored in several contexts. For instance, researchers have investigated its potential as an inhibitor of Janus kinases (JAKs), which are implicated in autoimmune diseases and cancer. The compound's ability to bind to JAK enzymes and modulate their activity has been highlighted in several publications, suggesting its utility as a lead compound for further development. Additionally, studies have shown that modifications to the methylimidazo[1,2-a]pyridine core can enhance binding affinity and selectivity towards specific targets.

The synthesis of 2,7-Dimethylimidazo[1,2-a]pyridin-3-amine typically involves multi-step organic reactions starting from readily available precursors. Common synthetic routes include cyclization reactions followed by functional group transformations to introduce the desired substituents. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making this compound more accessible for research purposes. Techniques such as transition metal-catalyzed cross-coupling reactions have been particularly useful in constructing the complex fused ring system characteristic of imidazopyridines.

Recent advancements in computational chemistry have also played a crucial role in understanding the properties of 2,7-Dimethylimidazo[1,2-a]pyridin-3-amine. Molecular modeling studies have provided insights into its binding interactions with biological targets at an atomic level. These simulations have helped researchers design more effective derivatives by predicting how structural modifications will affect binding affinity and selectivity. Such computational approaches are integral to modern drug discovery pipelines, allowing for rapid screening of virtual libraries before experimental validation.

The pharmacokinetic profile of 2,7-Dimethylimidazo[1,2-a]pyridin-3-amine is another critical aspect that has been examined in preclinical studies. Understanding how a compound is absorbed, distributed, metabolized, and excreted (ADME) is essential for assessing its potential as a therapeutic agent. Initial studies suggest that this compound exhibits moderate solubility in water and lipids, which could influence its bioavailability and distribution within the body. Further research is needed to optimize its pharmacokinetic properties through structural modifications.

In conclusion, 2 ,7 - Dimethylimidazo [ 1 , 2 - a ] py ridin -3 - am ine ( CAS No .801291 - 7 ) represents a promising scaffold for pharmaceutical development . Its unique structural features , combined with demonstrated biological activities , make it an attractive candidate for further investigation . As research continues to uncover new therapeutic targets , compounds like this one will play an increasingly important role in addressing unmet medical needs . The integration of cutting-edge synthetic techniques , computational methods , and preclinical studies ensures that future derivatives will be optimized for efficacy and safety . p >

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)